eculizumab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
eculizumab: clinical details
Prescribing considerations
- Confirm meningococcal immunisation status before initiation; vaccination does not eliminate infection risk.
- If urgent initiation precedes adequate vaccine protection, follow product requirements for appropriate antibacterial prophylaxis.
- Provide the patient guide and card, reinforcing immediate assessment of infection symptoms.
- Use caution with active systemic infection, especially possible Neisseria or encapsulated bacterial infection.
- Record the administered biological product name and batch number.
- Do not discontinue without a condition-specific plan.
Contraindications and cautions
- Hypersensitivity to eculizumab or a formulation excipient.
- Unresolved Neisseria meningitidis infection.
- Initiation without current meningococcal vaccination unless appropriate temporary antibiotic protection is provided.
- For selected BEKEMV: children below 2 years because intravenous sorbitol may be life-threatening in unrecognised hereditary fructose intolerance.
Monitoring
- Assess immediately for meningococcal infection, sepsis, severe infusion reaction or anaphylaxis.
- For PNH, monitor clinical haemolysis and lactate dehydrogenase.
- For aHUS, monitor platelet count, lactate dehydrogenase, creatinine and clinical thrombotic microangiopathy.
- Monitor closely for disease recurrence after interruption or discontinuation.
- Observe after infusion and assess infusion-related symptoms.
- Monitor effectiveness with IVIg, FcRn blockers or plasma interventions.
Clinical pharmacology
A recombinant humanised IgG2/4κ monoclonal antibody that binds C5 and blocks formation of the terminal complement complex C5b-9. It is catabolised to peptides and amino acids rather than undergoing conventional renal filtration or hepatic metabolism.
Formulation and product differences
- Selected BEKEMV is a biosimilar concentrate requiring dilution before intravenous infusion.
- BEKEMV contains sorbitol and polysorbate 80; its age and hereditary-fructose-intolerance restrictions are formulation-specific.
- The concentrate must not be given by intravenous push or bolus.
eculizumab preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 300 mg
eculizumab interactions
Tell the specialist team about all medicines and plasma-based procedures. Important interactions include:
Rituximab
Eculizumab may reduce rituximab's expected complement-dependent effect.
Plasma exchange or plasmapheresis
These procedures can substantially lower eculizumab concentrations and require specialist treatment adjustment.
Fresh frozen plasma infusion
May affect eculizumab exposure and requires coordination by the treating team.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.